Steven Burrill, the CEO of life science venture capital company Burrill & Co., spoke at a recent conference about some of the challenges facing the growth of personalized medicine in the United States and opportunities that could help in its development. Among the things that would change with the growth of personalized medicine is a shift in physicians roles from being determinants to critical advisers.
Burrill was speaking at a conference this week at a biotechnology industry event in Princeton, New Jersey hosted by BioNJ. Personalized medicine, also referred to as genomic medicine, is an approach to medicine in which individuals’ genome profiles are mapped out and assessed so that physicians can tailor the most effective treatment to the patient.
To read the full, original article click on this link: Steven Burrill: Physicians will shift from determinants to critical advisers
